Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN…
Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ Cells Data from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer…
Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential to…
Comprehensive Review of Overall Treatment Safety Profile of our ALLO-501/501A Candidate Used in Conjunction with Propriety Lymphodepletion with Investigational ALLO-647 from the Phase 1 ALPHA/ALPHA2 Studies Translational Overview of Patient…
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology…
SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™…
Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive…
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…